男性乳腺癌的生物学特性研究进展

Research development of biological profile of male breast cancer

男性乳腺癌(MBC)是一种少见且特殊的男性恶性肿瘤,由于生理因素等差异,其发病率远低于女性乳腺癌(FBC)。多项研究发现,在调整了肿瘤分期和年龄等因素后,MBC的预后与FBC类似,但激素受体、人表皮生长因子受体(HER-2)、Ki-67和BCL2的表达存在巨大差异。随着分子生物学的进步,乳腺癌基因组学的研究前景将更为广阔,对FBC和MBC之间的生物学差异的认识也会逐渐清晰。对MBC患者来说,这些差异对于肿瘤的预后和综合治疗可能具有重要价值。本研究结合近年来国内外相关文献,对MBC的分子生物学方面的研究进展作一概述,以进一步加强临床医师及患者的了解和重视。

Male breast cancer(MBC)is a rare and special male malignant tumor whose morbidity is much lower than that of female breast cancer(FBC)due to the different physiological factors.There have been multiple well-meaning attempts to show that,after adjusting for stage and age,the prognosis of MBC is similar to that of FBC,but there are vast differences in the expression of hormone receptors,HER-2,Ki-67 and BCL2.With developments in molecular biology and the transcriptosomic landscape of breast malignancy,there will be an increase in our knowledge of the molecular differences between breast cancer in females and males.For MBC patients,these differences may be of great importance for the prognosis and systemic therapy.Summing up the relevant literatures in China and abroad in recent years,this paper provides an overview of the molecular biology research progress of MBC,in order to strengthen the understanding and attention of clinicians and patients for MBC.